On August 7, 2023, Professor Mark A. Dawson from the Peter McCallum Cancer Center in Melbourne, Australia, and Dr. Oliver Rausch from Storm Therapeutics collaborated to publish an article titled "Introduction of METTL3 results in a cell invasive intervention response that enhances anti tumor immunity" in Cancer Discovery magazine. In this study, the research team found that inhibiting METTL3 stimulates cells to produce endogenous interferon responses through the formation of double stranded RNA. This immune regulatory mechanism is different from current immunotherapy drugs and provides an early preclinical scientific basis for enhancing anti-tumor effects when combined with anti PD1 immune checkpoint blockade.